Elevar Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Salt Lake City UT United States (2019)

Organization Overview

First Clinical Trial
2021
NCT05287360
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Elevar Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Elevar Therapeutics (0) Acquired (1)

lapatinib (tykerb) (8 trials)

Drugs in Phase 2 Trials (4)

Key: Elevar Therapeutics (0) Acquired (4)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (1 trial)

tipiracil (lonsurf) (1 trial)

trifluridine (viroptic) (1 trial)

Drugs in Phase 1 Trials (1)

Key: Elevar Therapeutics (0) Acquired (1)

nivolumab (opdivo) (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 8
  • # of Trial APIs: 6